Three hospital systems across the England began a clinical trial of a technology artificial intelligence (AI) designed to detect and classify the prostate cancer. The study – known as ARTICULATE PRO – is being carried out by the University of Oxford in collaboration with Paige – a pioneer in clinical applications of AI for cancer diagnosis.
ADVERTISING
Participating hospitals – North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust – are now incorporating Paige's AI technology into their standard care. This trial aims to evaluate the potential of AI to improve patient outcomes against a backdrop of rising prostate cancer cases.
Professor Clare Verrill, consultant in Cellular Pathology at OUH, associate professor and principal investigator of ARTICULATE PRO, told the portal AI News: “The central focus of ARTICULATE PRO is patients. We are striving to achieve our goal of ensuring they benefit the most from powerful AI technology in a safe and effective way.
“With multicenter live use of the Paige Prostate Suite, we can systematically study the benefits for patients in clinical settings.”
ADVERTISING
The Prostate Suite – the AI system being tested – is designed to assist pathologists in detecting, classifying and measuring tumors in prostate biopsies and tissue samples. Pathologists at the three hospitals are evaluating how this AI technology impacts their clinical decision-making, delivery of pathology services, and resource utilization in real-world scenarios.
The study is notable for its implementation in hospitals that use different digital pathology scanners and information systems, serving different patient populations. This diversity allows for a comprehensive assessment of how Paige's AI technology can better serve patients, histopathologists, and hospital systems in diagnosing prostate cancer.
As prostate cancer rates continue to rise, integrating AI into diagnosis can potentially lead to earlier detection, more accurate classification and, ultimately, better patient outcomes. The results of this trial could pave the way for wider adoption of AI in cancer diagnosis across the UK and beyond.
ADVERTISING
Read also
